-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2024-514688-24-00
9
2023-05-26
Patients with myelodysplastic syndrome (MDS), chronic myelomonocytic l
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2024-511219-78-00
5
2023-02-28
epithelial ovarian cancer
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2024-515924-35-00
6
2023-01-16
New-Onset Post-Operative Atrial Fibrillation after CABG
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-517382-17-00
4
2022-11-30
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2024-514641-12-00
5
2022-10-26
Transfusion-dependent β-thalassemia (TDT)
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2024-513978-22-00
5
2022-07-20
Severe sickle cell disease (SCD)
-
2023-509277-22-00
4
2022-06-22
Bronchiectasis
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-513349-35-00
5
2022-05-16
Transfusion-Dependent-Thalassemia
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2023-505163-37-00
3
2021-10-01
Metastatic Colorectal Cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-515708-38-01
7
2021-01-29
Heart failure
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia